| Description | hCAII-IN-9 is a potent carbonic anhydrase inhibitor that inhibits hCA II, hCA IX, and hCA XII with IC50s of 1.18 μM and 0.17 μM , and 2.99 μM , respectively. hCAII-IN-9 is not blood-brain barrier permeable. |
| In vitro | HCAII-IN-9 (Compound 11) (100 μM; 24-48 h) inhibits BHK-21 and HEK-293 cells with cell viability of 48% and 72%, respectively.[1] |
| Target activity | CA XII (human):2.99 μM, CA IX (human):0.17 μM, CA II (human):1.18 μM |
| molecular weight | 417.89 |
| Molecular formula | C15H16ClN3O5S2 |
| CAS | 2878477-18-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (131.61 mM) |
| References | 1. Hussain Z, et al. Synthesis and Evaluation of Amide and Thiourea Derivatives as Carbonic Anhydrase (CA) Inhibitors. ACS Omega. 2022;7(50):47251-47264. |